Liquidia’s customer map: one commercial partner drives the economics

Liquidia Technologies operates as a commercial-stage biopharma company that licenses and promotes a hospital/specialty injectable (Treprostinil Injection) under an exclusive Promotion Agreement, collecting profit share and service revenue tied to U.S. sales while maintaining limited in‑house product manufacturing exposure. The company’s revenue is overwhelmingly concentrated in that promotional relationship, so investors should treat Liquidia as a specialized commercial operator where partner performance, reimbursement dynamics, and competitor generic launches directly determine cash flow variability. For a concise view of third‑party exposure and commercial counterparties, visit https://nullexposure.com/.

Why the commercial agreement matters more than a typical product portfolio

Liquidia’s business model is not broad-based product sales; it is a services-and-profit-share model centered on a Promotion Agreement that grants exclusive U.S. promotional rights for Treprostinil Injection and yields nearly all reported revenue. This contractually defined posture creates distinct operating characteristics: high counterparty concentration, a defined but critical revenue stream, and operational dependence on partner distribution and specialty pharmacy inventories rather than internal manufacturing scale.

Concentration: Liquidia reports that roughly 98% and 99% of revenue in 2024 and 2023, respectively, derived from the Promotion Agreement — a structural concentration that converts any partner disruption into material top‑line risk (company filings, FY2024).
Contracting posture and criticality: The Promotion Agreement gives Liquidia exclusive promotional rights in the U.S., which makes the partner relationship both strategic and critical to near‑term results (company filings, FY2024).
Maturity and active relationship dynamics: The agreement is active and includes mechanics like refund liabilities that reduce future net receipts, indicating ongoing commercial settlements rather than a one‑time licensing event (company filings, FY2024).

If you want a deeper, machine‑assisted breakdown of counterparties, check https://nullexposure.com/.

What each named relationship means for investors

Below are the counterparties mentioned in Liquidia’s publicly available disclosures and news coverage, summarized plainly with source context.

Sandoz, Inc.

Liquidia’s commercial economics are anchored to a Promotion Agreement with Sandoz, under which Liquidia conducts exclusive U.S. promotional activities for Treprostinil Injection and shares profits from U.S. sales; this agreement generated approximately 98–99% of reported revenue in recent years and is the primary driver of accounts receivable concentration. According to Liquidia’s FY2024 Form 10‑K, the Promotion Agreement is the company’s revenue engine (Liquidia 10‑K, FY2024).
Company press and reporting in early 2026 reaffirm that service revenue is primarily related to the Sandoz promotion agreement, and industry reporting noted that the launch of YUTREPIA changed field-force allocations away from the injection product, affecting promotional dynamics (Liquidia press release, March 5, 2026; TradingView coverage, March 2026).

One large unnamed customer (accounts receivable concentration)

Liquidia disclosed that one customer accounted for 95% and 99% of accounts receivable as of December 31, 2024 and 2023, respectively, signaling extreme receivable concentration that reflects the profit‑share cash flow mechanics of the Promotion Agreement (Liquidia 10‑K, FY2024).

Dr. Reddy’s Laboratories Inc.

Dr. Reddy’s launched a generic treprostinil for parenteral administration in April 2023, creating additional market competition in the treprostinil space that influences pricing, hospital formulary choices, and the addressable market for promoted injectable products (Liquidia 10‑K, FY2024).

Par Pharmaceutical, Inc.

Par Pharmaceutical launched a generic treprostinil for parenteral use after FDA approval in September 2019 and sells primarily to hospitals; this competitor presence is a commercial headwind that affects volume and pricing dynamics for the promoted product (Liquidia 10‑K, FY2024).

Teva Pharmaceutical Industries Ltd.

Teva introduced a generic treprostinil for parenteral administration in October 2019 distributed mainly via specialty pharmacies and hospitals, adding another source of generic supply that competes with the branded or promoted injectable in the same channels Liquidia targets (Liquidia 10‑K, FY2024).

Each of the above references comes from Liquidia’s FY2024 annual filing or subsequent press coverage; they collectively sketch a competitive backdrop where multiple generic entrants coexist with Liquidia’s promoted injection.

Interpreting the constraints: how to think about operating risk

Liquidia’s disclosures and derived constraints produce a crisp investor-focused checklist:

High commercial concentration: Company‑level signal — revenue is overwhelmingly tied to the Promotion Agreement (company filings, FY2024). This elevates counterparty risk and compresses diversification benefits that typical product portfolios provide.
Critical partner dependency: The Promotion Agreement is operationally critical; failure or renegotiation of terms would materially change cash flows (company filings, FY2024).
Geographic concentration: The Promotion Agreement grants exclusivity for U.S. promotional activities, so growth and downside scenarios are heavily U.S.-centric (Promotion Agreement excerpt, August 2018; filings).
Active, maturing commercial relationship: The company recognizes refund liabilities offset against receivables and continues to share profits, indicating ongoing settlements rather than a static royalty stream (company filings, FY2024).
Channel sensitivity: Liquidia’s ability to reach patients depends on specialty pharmacies and hospital inventory availability, so distribution interruptions or inventory shortfalls in those channels would directly impact sales (company filings, FY2024).

These characteristics make Liquidia resemble a commercial services firm with product dependency rather than a diversified drugmaker; valuation should therefore emphasize counterparty credit, reimbursement stability, and competitive intensity.

Key takeaways for investors

One contract drives nearly all revenue; that creates binary outcomes tied to partner execution and competitive activity.
Receivable and revenue concentration are high, revealing settlement dynamics and potential cashflow volatility.
Multiple generic entrants (Dr. Reddy’s, Par, Teva) are active in the treprostinil market, elevating competitive pressure on pricing and volumes.

If you want a structured view of counterparties and their contractual footprints, visit https://nullexposure.com/ for in‑depth commercial relationship analytics.

Final thoughts and next steps

Liquidia’s financial profile reflects a single‑partner commercialization model: strong near‑term revenue visibility if the Promotion Agreement performs, with elevated downside if partner sales weaken or generics compress margins. For investors and operators, focus analysis on partner receivables, refund mechanics, field‑force allocation changes (e.g., impacts from YUTREPIA), and hospital/specialty pharmacy stocking trends. For continued tracking of these commercial relationships and to help prioritize counterparty risk in due diligence, see https://nullexposure.com/.

Bold, fact‑based monitoring of partner performance and competitor launches is the most efficient way to convert Liquidia’s concentrated exposure into an actionable investment thesis.